Dr. Holland's innate persistence and determination paid off as she tackled one early challenge of establishing the field of psycho-oncology as a quantifiable science: resistance. "Negative attitudes toward psychological problems were a big barrier, and also scientists didn't believe you could measure people's emotions," she says. "We had to show that we could do the science to get to the table."
Toward that end, she and colleagues developed quantitative measures for demonstrating how patients were faring psychologically and whether or not specific interventions were proving effective. The field now is an accepted subspecialty in oncology, and the National Comprehensive Cancer Network (NCCN) has since developed clinical practice guidelines for managing distress.
Building on Progress
It is a testimony to the work of Dr. Holland and her colleagues that a 2008 IOM report entitled Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs concluded that it is not possible to provide high-quality cancer care without assessing psychosocial health needs and providing psychosocial health services. 3 The report's authors defined the "psychological and social services and interventions that enable patients, their families, and health care providers to optimize biomedical health care and to manage the psychological/behavioral and social aspects of illness and its consequences so as to promote better health."
The IOM report led the American College of Surgeons Commission on Cancer to stipulate in its 2012 patient-centered standards that by 2015, all 1500 of the cancer centers that it accredited had to screen patients for distress and refer those experiencing it to psychosocial services. "It's just being implemented, but it has started," Dr. Holland affirms. "We screen people for distress on a scale of 1 to 10 and then ask them what's going on, if it's social, psychological, financial, or spiritual." Patients are then referred to the appropriate services, although some centers provide more assistance than others. The NCCN has just published these guidelines in patient-friendly language to better inform people across the country about issues of distress and available resources, she adds.
There are an estimated 15.5 million cancer survivors in the United States, and with that number expected to increase to more than 20 million by 2026 according to the ACS, the psycho-oncology field is expected to play a crucial role in helping this burgeoning population. Some of the areas on which Dr. Holland and her colleagues are focusing at MSKCC include the following: "meaning" psychotherapy to help patients who have limited time to live explore questions such as what is most important to them during this time; a smoking cessation group; and a communications skills laboratory that teaches physicians how to better communicate with patients regarding diagnoses, prognoses, and side effects.
A Woman of Purpose
Born and raised on a farm outside Dallas, Texas, and a high school student at the beginning of World War II, Jimmie Holland had always wanted to become a physician. Realizing a goal that few women at that time dared to pursue, she graduated from Baylor College of Medicine in 1952. Her initial plan was to go into family medicine, but in working with schizophrenia patients, she soon became fascinated by psychiatry.
When Dr. Holland's first husband died half-way through her psychiatric residency, she moved to Massachusetts General. This was during the last year of the polio epidemic, and that experience, she says, gave her "a chance to study how people react to illness." Shortly thereafter, she met and married Dr. James Holland, and the two moved to Buffalo, New York, where he joined Roswell Park Cancer Institute and became chairman of Acute Leukemia Group B, the first National Cancer Institute clinical trial cooperative group. They went on to raise 5 children while she taught and treated patients part-time at the State University of New York at Buffalo. They worked for a year in Russia in 1972, their children attending public school there. Upon the couple's return, Dr. James Holland joined the faculty of Mount Sinai Hospital in New York City, whereas Dr. Jimmie Holland began working at Montefiore Medical Center and ultimately joined MSKCC.
Dr. Holland continues to work and write and to squeeze in time to do some cooking and enjoy her family. Following in the footsteps of their famous parents, 2 of the Holland children also entered the medical field, and a granddaughter is about to start medical school. Dr. Holland is also thinking about writing a new edition of her book published in 2000. 1 As she happily notes, a lot has changed in the field since then.
A study of randomly selected teenagers has led researchers to conclude that teen vaping may act as a "one-way bridge" to smoking for teens who have never before smoked. Furthermore, results show that vaping may not stop those who have smoked before from returning to smoking.
The online study followed a sample of 17-to 18-year-olds who had been randomly selected from a representative survey of more than 13,000 12th graders from 122 schools. 1 The survey, known as Monitoring the Future, is conducted annually by researchers at the University of Michigan. The 347 respondents were initially surveyed during their senior year of high school in 2014 and again in 2015.
Vaping is the use of battery-powered devices equipped with a heating element that produces an aerosol, or vapor,
Researchers Call Teen Vaping "One-Way Bridge" to Smoking
that is inhaled by users. The devices are known as electronic or e-cigarettes. E-cigarette liquid is available in a variety of flavors that appeal to many teens and may or may not contain nicotine, and vaping is widely perceived as less harmful than traditional cigarettes. According to lead author Richard Miech, PhD, of the University of Michigan Institute for Social Research, vaping has increased significantly in popularity among teens: ranking at nearly zero usage in 2011, it has become one of the most common forms of substance use among teens today.
Dr. Miech notes that vaping changes teens' perceptions of smoking risks and leads them to be less likely than nonvapers to believe that smoking is harmful. Researchers' analysis of responses showed that e-cigarettes were one of the most popular forms of substance use among teens, with the prevalence of vaping (within the past 30 days) being approximately 50% higher than the prevalence of conventional smoking. Most of the respondents thought that cigarette smoking was harmful, with 80% in both the 2014 and follow-up surveys saying that 1 or more packs daily posed a "great risk." However, among teens who had never smoked a cigarette, recent vapers were 4 times more likely than nonvapers to move away from the view that cigarette smoking poses a "great risk"
Additional results of the study were as follows:
Teens who had never smoked a cigarette before reaching 12th grade but who had used an e-cigarette at least once within the past 30 days were more than 4 times as likely to say that they had smoked a cigarette by the follow-up survey (31%) as those who had not vaped (7%). That difference held true regardless of potentially influential factors such as sex, ethnicity, and parents' education level.
All the new smokers at follow-up who had recently vaped at baseline said that they had smoked "once or twice" during the preceding 12 months.
For those who had ever smoked by the time of the baseline survey, the prevalence of smoking during the preceding 12 months was more than twice as high among teens who were also vapers (80%) in comparison with those who were not (37%).
Vaping also significantly predicted cigarette smoking in the preceding 12 months at the follow-up survey among teens who had smoked at some point previously but not recently (63% of vapers vs 27% of nonvapers, even among those who felt that smoking was very harmful). 1 Despite recommendations that high-risk current and former smokers be screened, rates did not improve, and the authors point to the need to educate clinicians as well as people at risk for the disease about the importance of screenings.
The US Preventive Services Task Force (USPSTF) in 2013 recommended annual screening for lung cancer with low-dose computed tomography (LDCT) for people who are 55 to 80 years old and have a smoking history of at least 30 packs per year. The recommendation followed findings by the National Lung Screening Trial showing that screening this high-risk group could reduce its lung cancer mortality by 20%.
In 2010, before the USPSTF recommendation, the National Health Interview Survey determined that only 2% to 4% of highrisk smokers received LDCT screening in the previous year.
The ACS research team, led by Ahmedin Jemal, DVM, PhD, compared responses from the National Health Interview Survey between 2010 and 2015 and included only those people who would have met the USPSTF screening recommendations. The investigators found that the proportion of eligible respondents who reported LDCT screening in the past 12 months remained low and constant between the 2 survey years: 3.3% in 2010 and 3.9% in 2015. According to the authors' estimate, of the 6.8 million current and former smokers who were eligible for screening in 2015, only 262,700 received it.
Dr. Jemal says the reason that screening uptake is so low is likely a lack of knowledge among smokers and physicians about the benefits of screening as well as a lack of access to high-quality screening facilities. He adds that in a previous study, his team determined that implementing quality screening broadly across the country could prevent approximately 12,000 lung cancer deaths annually in the short term.
